Medtronic plc (NYSE:MDT) posted better-than-expected earnings for the first quarter and announced key board appointments on Tuesday, naming John Groetelaars and Bill Jellison as independent directors, effective immediately.
Medtronic reported strong first-quarter 2026 results, with sales hitting $8.58 billion, surpassing the consensus estimate of $8.38 billion. This marks an 8.4% increase year-over-year, with organic growth of 4.8%. Adjusted earnings of $1.26 per share also beat expectations of $1.23.
Medtronic reiterated its fiscal year 2026 organic revenue growth guidance of 5%. The company revised its fiscal 2026 revenue growth on a reported basis from 4.8%-5.1% to 6.5%-6.8%. It …